OBJECTIVES: Pharmacologic evidence suggests adequate antiplatelet activity in diabetic patients requires >100 mg aspirin daily, yet recent trials have used ≤100 mg daily. This meta-analysis explored the relationship between aspirin dose and prevention of cardiovascular events. DATA SOURCES: Six electronic databases were searched using database-appropriate terms for aspirin, diabetes, and comparative study from inception until February 2010. REVIEW METHODS: Randomized controlled trials and cohort studies comparing aspirin to no antiplatelet therapy were included if they reported cardiovascular events as pre-specified outcomes, aspirin dose, and number of diabetic patients. Studies were stratified by daily aspirin dose (≤100 mg; 101-325 mg; >325 mg) and pooled risk ratios (RR) were calculated using random effects models. All-cause mortality was the primary outcome of interest. Cardiovascular-related mortality, myocardial infarction, and stroke were secondary outcomes. RESULTS: Data for diabetic patients were available from 21 studies (n = 17,522). Overall, 1,172 (15.4%) of 7,592 aspirin users and 1,520 (18.4%) of 8,269 controls died (p = 0.31). The pooled RRs were 0.89 (95% CI: 0.72-1.10; p = 0.27) from 13 studies using ≤100 mg (I(2) = 64%); 0.89 (95% CI: 0.61-1.30; p = 0.55) from four studies using 101-325 mg (I(2) = 83%); and 0.96 (95% CI: 0.85-1.08; p = 0.50) from eight studies using >325 mg (I(2) = 0%). Aspirin use was associated with a significantly lower risk of mortality (RR: 0.82; 95% CI: 0.69-0.98; p = 0.03) in 13 secondary prevention studies (I(2) = 27%), whereas aspirin use in seven primary prevention studies (I(2) = 0%) was not (RR: 1.01; 95% CI 0.85-1.19; p = 0.94). A substantial amount of heterogeneity was observed amongst studies in all outcomes. Although inclusion of cohort studies was a major source of heterogeneity, stratification by study design did not reveal a significant dose-response relationship. CONCLUSIONS/ INTERPRETATION: This summary of available data does not support an aspirin dose-response effect for prevention of cardiovascular events in diabetic patients. However, the systematic review identified an important gap in randomized controlled trial evidence for using 101-325 mg aspirin daily in diabetes.
OBJECTIVES: Pharmacologic evidence suggests adequate antiplatelet activity in diabeticpatients requires >100 mg aspirin daily, yet recent trials have used ≤100 mg daily. This meta-analysis explored the relationship between aspirin dose and prevention of cardiovascular events. DATA SOURCES: Six electronic databases were searched using database-appropriate terms for aspirin, diabetes, and comparative study from inception until February 2010. REVIEW METHODS: Randomized controlled trials and cohort studies comparing aspirin to no antiplatelet therapy were included if they reported cardiovascular events as pre-specified outcomes, aspirin dose, and number of diabeticpatients. Studies were stratified by daily aspirin dose (≤100 mg; 101-325 mg; >325 mg) and pooled risk ratios (RR) were calculated using random effects models. All-cause mortality was the primary outcome of interest. Cardiovascular-related mortality, myocardial infarction, and stroke were secondary outcomes. RESULTS: Data for diabeticpatients were available from 21 studies (n = 17,522). Overall, 1,172 (15.4%) of 7,592 aspirin users and 1,520 (18.4%) of 8,269 controls died (p = 0.31). The pooled RRs were 0.89 (95% CI: 0.72-1.10; p = 0.27) from 13 studies using ≤100 mg (I(2) = 64%); 0.89 (95% CI: 0.61-1.30; p = 0.55) from four studies using 101-325 mg (I(2) = 83%); and 0.96 (95% CI: 0.85-1.08; p = 0.50) from eight studies using >325 mg (I(2) = 0%). Aspirin use was associated with a significantly lower risk of mortality (RR: 0.82; 95% CI: 0.69-0.98; p = 0.03) in 13 secondary prevention studies (I(2) = 27%), whereas aspirin use in seven primary prevention studies (I(2) = 0%) was not (RR: 1.01; 95% CI 0.85-1.19; p = 0.94). A substantial amount of heterogeneity was observed amongst studies in all outcomes. Although inclusion of cohort studies was a major source of heterogeneity, stratification by study design did not reveal a significant dose-response relationship. CONCLUSIONS/ INTERPRETATION: This summary of available data does not support an aspirin dose-response effect for prevention of cardiovascular events in diabeticpatients. However, the systematic review identified an important gap in randomized controlled trial evidence for using 101-325 mg aspirin daily in diabetes.
Authors: Marcel M C Hovens; Jaapjan D Snoep; Jeroen C J Eikenboom; Johanna G van der Bom; Bart J A Mertens; Menno V Huisman Journal: Am Heart J Date: 2007-02 Impact factor: 4.749
Authors: Lars Rydén; Eberhard Standl; Małgorzata Bartnik; Greet Van den Berghe; John Betteridge; Menko-Jan de Boer; Francesco Cosentino; Bengt Jönsson; Markku Laakso; Klas Malmberg; Silvia Priori; Jan Ostergren; Jaakko Tuomilehto; Inga Thrainsdottir; Ilse Vanhorebeek; Marco Stramba-Badiale; Peter Lindgren; Qing Qiao; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; John Camm; Veronica Dean; Jaap Deckers; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; João Morais; Ady Osterspey; Juan Tamargo; José Luis Zamorano; Jaap W Deckers; Michel Bertrand; Bernard Charbonnel; Erland Erdmann; Ele Ferrannini; Allan Flyvbjerg; Helmut Gohlke; Jose Ramon Gonzalez Juanatey; Ian Graham; Pedro Filipe Monteiro; Klaus Parhofer; Kalevi Pyörälä; Itamar Raz; Guntram Schernthaner; Massimo Volpe; David Wood Journal: Eur Heart J Date: 2007-01 Impact factor: 29.983
Authors: John B Buse; Henry N Ginsberg; George L Bakris; Nathaniel G Clark; Fernando Costa; Robert Eckel; Vivian Fonseca; Hertzel C Gerstein; Scott Grundy; Richard W Nesto; Michael P Pignone; Jorge Plutzky; Daniel Porte; Rita Redberg; Kimberly F Stitzel; Neil J Stone Journal: Diabetes Care Date: 2007-01 Impact factor: 19.112
Authors: Richard M Cubbon; Christopher P Gale; Adil Rajwani; Afroze Abbas; Christine Morrell; Raj Das; Julian H Barth; Peter J Grant; Mark T Kearney; Alistair S Hall Journal: Diabetes Care Date: 2007-10-24 Impact factor: 19.112
Authors: Sheena S Mehta; Robert J Silver; Arthur Aaronson; Martin Abrahamson; Allison B Goldfine Journal: Am J Cardiol Date: 2006-01-06 Impact factor: 2.778
Authors: Joseph DiChiara; Kevin P Bliden; Udaya S Tantry; Miruais S Hamed; Mark J Antonino; Thomas A Suarez; Oscar Bailon; Anand Singla; Paul A Gurbel Journal: Diabetes Date: 2007-09-11 Impact factor: 9.461
Authors: James F Meschia; Cheryl Bushnell; Bernadette Boden-Albala; Lynne T Braun; Dawn M Bravata; Seemant Chaturvedi; Mark A Creager; Robert H Eckel; Mitchell S V Elkind; Myriam Fornage; Larry B Goldstein; Steven M Greenberg; Susanna E Horvath; Costantino Iadecola; Edward C Jauch; Wesley S Moore; John A Wilson Journal: Stroke Date: 2014-10-28 Impact factor: 7.914
Authors: Nicola Veronese; Jacopo Demurtas; Trevor Thompson; Marco Solmi; Gabriella Pesolillo; Stefano Celotto; Tommaso Barnini; Brendon Stubbs; Stefania Maggi; Alberto Pilotto; Graziano Onder; Evropi Theodoratou; Alberto Vaona; Joseph Firth; Lee Smith; Ai Koyanagi; John P A Ioannidis; Ioanna Tzoulaki Journal: Br J Clin Pharmacol Date: 2020-06-02 Impact factor: 4.335
Authors: Marcello Casaccia Bertoluci; Augusto Pimazoni-Netto; Antonio Carlos Pires; Antonio Eduardo Pesaro; Beatriz D Schaan; Bruno Caramelli; Carisi Anne Polanczyk; Carlos Vicente Serrano Júnior; Danielle M Gualandro; Domingos Augusto Malerbi; Emilio Moriguchi; Flavio Antonio de Oliveira Borelli; João Eduardo Nunes Salles; José Mariani Júnior; Luis Eduardo Rohde; Luis H Canani; Luiz Antonio Machado Cesar; Marcos Tambascia; Maria Tereza Zanella; Miguel Gus; Rafael Selbach Scheffel; Raul Dias Dos Santos Journal: Diabetol Metab Syndr Date: 2014-05-20 Impact factor: 3.320
Authors: Miguel Á Salinero-Fort; Francisco Javier San Andrés-Rebollo; Carmen de Burgos-Lunar; Francisco Jesús Arrieta-Blanco; Paloma Gómez-Campelo Journal: PLoS One Date: 2013-10-17 Impact factor: 3.240